Among them, the most common AEs were dizziness (16.3% in mGluR5 antagonist groups vs. 4.3% in placebo groups), visual hallucination (10.1 vs. 1.1%), fatigue (10.1 vs. 4.8%), insomnia (6.1 vs. 1.6%), nasopharyngitis (6.1 vs. 1.6%) and diarrhea (5.1 vs. 2.1%). Here, GRM5 is linked to nasopharyngitis.